๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06409429Pancreatic Cancer
DrugsGX·Nimotuzumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3
146
Tianjin
2024-05-01
Not yet open
To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia
NCT06405711Myopia, Progressive
Tianjin Eye Hospital
Not applicable
138
Tianjin
2024-05
Active, closed
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
NCT06464185B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
53
Tianjin
2024-04-30
Not yet open
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
NCT06387420ACUTE MYELOID LEUKEMIA; AML
Akeso
Phase 1/2
180
Tianjin
2024-04-29
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Recruiting
The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction
NCT06374667Stroke, Acute Ischemic, Blood-Brain Barrier
yilong Wang
Not applicable
134
Wuhu, Beijing, Tangshan, Xi'an, Tianjin
2024-04-22
Recruiting
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
NCT06730659Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
Phase 1
36
Tianjin
2024-04-19
Recruiting
Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
NCT06548711Postoperative Cough, Lung Cancer
Kong Fanming
Not applicable
84
Tianjin
2024-04-17
Recruiting
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
NCT06447090Relapse Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2024-04-12
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guรฉrin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan
2024-04-09
Recruiting
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
NCT06363734Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation, EGFR-TKI Resistant Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2
32
Tianjin
2024-04-09
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT06484790Tumor, Solid
DrugsNW-301D·NW-301V
Ting Deng
Phase 1
9
Tianjin
2024-04-08
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
ฮ’-Thalassemia Treatment with KL003 Cell Injection
NCT06280378Transfusion-dependent Beta-Thalassemia
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Phase 1/2
41
Shanghai, Tianjin
2024-04-05
Recruiting
Comparison of Compressed Continuous Suture and Conventional Suture in Pterygium Surgery
NCT07244276Primary Pterygium
Tianjin Eye Hospital
Not applicable
40
Tianjin
2024-04-02
Recruiting
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
NCT06387121Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drugs6-mercaptopurine·Inotuzumab ozogamicin·Blinatumomab·Methotrexate
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
53
Tianjin
2024-04-02
Recruiting
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
NCT06327451Glioblastoma, IDH-wildtype
DrugAtorvastatin
Tianjin Medical University General Hospital
Phase 2
50
Tianjin
2024-04-01
Active, closed
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
NCT06569108Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor
Suzhou Alphamab Co., Ltd.
Phase 3
125
Tianjin
2024-04-01
Recruiting
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
NCT07657325Renal Cell Carcinoma (RCC)
DrugTislelizumab
Tianjin Medical University Second Hospital
Observational
110
Tianjin
2024-04-01
Not yet open
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
NCT06318884Non-Hodgkin Lymphoma, B-cell
Sinocelltech Ltd.
Phase 1
76
Beijing, Zhengzhou, Tianjin
2024-04
Recruiting
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
NCT06461351B-cell Tumors
Juventas Cell Therapy Ltd.
Observational
1,000
Tianjin
2024-03-30
Recruiting
Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia
NCT06725212Benign Prostatic Hyperplasia
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
NCT06752746Polycythemia Vera
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
Recruiting
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
NCT06221670NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
51
Tianjin
2024-03-20
Recruiting
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
NCT06301399Advanced Hepatocellular Carcinoma
DrugsPD-1·Rituximab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-03-20
Recruiting
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
NCT06206174Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
Shenzhen TargetRx Co., Ltd.
Phase 1/2
30
Tianjin
2024-03-06
Recruiting
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327Immune Thrombocytopenia, Treatment
DrugAvatrombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2024-03-01
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
By invitation
Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjรถgren's Syndrom
NCT07171710Dry Eye Disease
Tianjin Eye Hospital
Not applicable
30
Tianjin
2024-03-01
Recruiting
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
NCT06208137Transplant-Related Disorder
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
456
Tianjin
2024-02-29
Recruiting
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
NCT06265545AML, Refractory, Relapsed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
458
Tianjin
2024-02-22
By invitation
Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
NCT07162467Schizophrenia
Tianjin Anding Hospital
Observational
200
Tianjin
2024-02-19
Recruiting
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
NCT06196203Higher-risk Myelodysplastic Syndromes
DrugsAK117·Azacitidine
Akeso
Phase 2
90
Tianjin
2024-02-07
Active, closed
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06238544Paroxysmal Nocturnal Hemoglobinuria
DrugHRS-5965
Chengdu Suncadia Medicine Co., Ltd.
Phase 2
132
Beijing, Tianjin
2024-02-06
Active, closed
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure โ‰ฅ3 Lines of Therapy.
NCT06231368Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
6
Tianjin
2024-02-04
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
NCT06355739B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
Zhu Xiaofan
Not applicable
60
Tianjin
2024-02-01
Recruiting
Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control
NCT06523504Myopia
Ruihua Wei
Phase 1/2
410
Tianjin
2024-02-01
Active, closed
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06196840Neovascular Age-Related Macular Degeneration
DrugAflibercept
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
A Single-Arm Clinical Trial of Percutaneous Splenic Ablation Combined With Splenic Artery Occlusion for Secondary Hypersplenism.
NCT06292715Secondary Hypersplenism
Tianjin Medical University Cancer Institute and Hospital
Not applicable
35
Tianjin
2024-01-20
Recruiting
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
NCT06238908Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
6
Tianjin
2024-01-17
Recruiting
GVMยฑR in Patients With Relapsed or Refractory Aggressive NHL.
NCT06244368Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
115
Tianjin
2024-01-17
Recruiting
Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
NCT05369351Intracerebral Haemorrhage
DrugMirabegron
Tianjin Medical University General Hospital
Phase 2
25
Tianjin
2024-01-17
Active, closed
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
NCT06199089Immune Thrombocytopenia, Treatment
DrugCM313
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-01-16
Active, closed
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
NCT06312475Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Suzhou Alphamab Co., Ltd.
Phase 3
53
Tianjin
2024-01-09
Recruiting
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
NCT06278454Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer, Lymph Node Metastases
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
Recruiting
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
NCT06219239Transfusion-dependent Beta-Thalassemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
3
Tianjin
2024-01-04
Recruiting
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
NCT06179524Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
Beijing Yongtai Ruike Biotechnology Company Ltd
Phase 2
100
Tianjin
2024-01-03
Recruiting
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07256301PNH - Paroxysmal Nocturnal Hemoglobinuria
DrugEA5
Shanghai Lanyi Therapeutics Co., Ltd.
Phase 1
24
Tianjin, Hangzhou
2024-01-03
Active, closed
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT06547944Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
DrugsZanubrutinib·Obinutuzumab·Lenalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2024-01-01
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Recruiting
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-28
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647Hypoxia, Gastric Polyp, Colon Cancer, Esophageal Cancer
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xiโ€™an, Tianjin, Hangzhou
2023-12-27
Active, closed
Spectacle Films Utilising S.T.O.P.ยฎ Technology for Slowing Down Myopia Progression in Children
NCT06137560Myopia
nthalmic Pty Ltd
Not applicable
210
Tianjin, Shanghai
2023-12-22
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
DrugsMomelotinib·Ruxolitinib
Janssen Research & Development, LLC
Phase 1
300
Beijing, Tianjin
2023-12-20
Recruiting
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)
NCT06412224PDR - Proliferative Diabetic Retinopathy
DrugRRG001
Li Xiaorong
Phase EARLY_PHASE1
6
Tianjin
2023-12-20
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
NCT06141460Neovascular Age-related Macular Degeneration
DrugRRG001
Shanghai Refreshgene Technology Co., Ltd.
Phase 1/2
48
Tianjin
2023-12-12
Recruiting
Optimal Evaluation to Reduce Cardiovascular Imaging Testing
NCT05640752Chronic Coronary Syndrome
Tianjin Chest Hospital
Not applicable
800
Beijing, Lanfang, Tianjin
2023-12-11
Recruiting
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
NCT06224257Relapsed/Refractory Large Granular T Lymphocytic Leukemia
DrugLinperlisib
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
41
Hefei, Zhoukou, Tianjin
2023-12-03
Recruiting
Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients
NCT06108830Sleep Disturbance
DrugsEsketamine and remimazolam·Remimazolam·Esketamine
Tianjin Medical University General Hospital
Not applicable
400
Tianjin
2023-12-01
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06094881Immune Thrombocytopenia, Treatment
DrugObinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-01
Recruiting
Anti-CD38 Antibody Treating Evans Syndrome
NCT06014775Evan Syndrome, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2023-12-01
Not yet open
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
NCT06147375Immune Tolerance, Immunosuppression, Liver Transplant; Complications
Wei Gao
Not applicable
47
Tianjin
2023-12-01
Not yet open
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
NCT06136988Locally Advanced Unresectable Esophageal Squamous Carcinoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
129
Jinan, Tianjin
2023-12
Recruiting
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
NCT06158269Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-12
Recruiting
Cohort of Nursing Homes
NCT07249086Health Status
Institute of Hematology & Blood Diseases Hospital, China
Observational
1,500
Tianjin
2023-11-30
Recruiting
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
NCT05888870Hemophilia A With Inhibitor
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
50
Tianjin
2023-11-22
Active, closed
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
DrugsTrastuzumab emtansine·Trastuzumab Rezetecan
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Recruiting
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
NCT06123754Non-small Cell Lung Cancer
3D Medicines (Sichuan) Co., Ltd.
Phase 3
390
Tianjin
2023-11-17
Recruiting
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
NCT06091124Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
DrugsCDDP·Etoposide·Adebrelimab·Cisplatin
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Recruiting
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
NCT06102694Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-16
Recruiting
Gene Therapy for DME
NCT06492876Diabetic Macular Edema
Frontera Therapeutics
Phase 1/2
78
Tianjin
2023-11-15
Recruiting
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05960955Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 2
90
Tianjin
2023-11-13
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Recruiting
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
NCT06102772Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
30
Tianjin
2023-11-10
Recruiting
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
NCT06102785Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
30
Tianjin
2023-11-10
Recruiting
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed
NCT06102759Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
30
Tianjin
2023-11-10
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
NCT06093438Cervical Cancer, Induction Chemotherapy, Immunotherapy
DrugTislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
20
Tianjin
2023-11-01
Recruiting
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582Primary Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-01
Recruiting
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
NCT07130565Amyloid, Cardiac Amyloidosis, Amyloidosis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2023-11-01
Recruiting
Effect and Mechanism of Brain Stimulation for Parkinson's Disease With Cognitive Impairment
NCT06090682Parkinson Disease, Cognitive Impairment
Tianjin Huanhu Hospital
Observational
200
Tianjin
2023-11-01
Recruiting
Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy (PROTECT-2)
NCT05789823Acute Ischemic Stroke
Capital Medical University
Phase 2
160
Tianjin
2023-11-01
Recruiting
IN10018 Combination Therapy in Treatment-naรฏve ES-SCLC
NCT06030258Small Cell Lung Cancer Extensive Stage
DrugsIN10018·Etoposide·Tislelizumab·Carboplatin
InxMed (Shanghai) Co., Ltd.
Phase 1/2
120
Jinan, Tianjin, Zhengzhou
2023-10-30
Recruiting
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
NCT06061146Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
136
Tianjin
2023-10-05
Active, closed
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy
NCT06066242Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
113
Tianjin
2023-10-01
By invitation
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
NCT07356765Schizophrenia, Negative Symptoms of Schizophrenia
DrugBerberine
Tianjin Anding Hospital
Not applicable
120
Tianjin
2023-09-26
Active, closed
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
NCT05987358Biliary Carcinoma
DrugTQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Active, closed
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 3
30
Guangzhou, Chongqing, Shanghai, Tianjin
2023-09-13
Recruiting
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
NCT06000956Ankylosing Spondylitis
Tasly Pharmaceutical Group Co., Ltd
Phase 3
408
Beijing, Lanzhou, Shijiazhuang, Luoyang, Wuhan, Suzhou, Nanchong, Tianjin
2023-09-11
Recruiting
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
NCT06047197Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Beijing Yongtai Ruike Biotechnology Company Ltd
Phase 1
25
Tianjin
2023-09-05
Active, closed
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
NCT06340048Heart Failure
DrugHiCM-188 therapy
HELP Therapeutics Co., Ltd.
Phase 1/2
36
Tianjin
2023-09-05
Recruiting
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
NCT06031727Neovascular Age-related Macular Degeneration(nAMD)
HuidaGene Therapeutics Co., Ltd.
Phase EARLY_PHASE1
12
Shanghai, Tianjin
2023-09-04
Recruiting
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
NCT06208826Head and Neck Cancer
DrugsCisplatin·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
268
Tianjin
2023-09-01
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
NCT05995054Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
110
Tianjin
2023-08-28
Recruiting
AK104 for Recurrent or Metastatic Vulvar Cancer
NCT05932212Vulvar Cancer
DrugsCadonilimab·Cisplatin·Carboplatin·Paclitaxel
Akeso
Phase 2
20
Fuzhou, Guangzhou, Shijiangzhuang, Shenyang, Tianjin, Hangzhou
2023-08-25
Active, closed
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978Relapsed/Refractory Chronic Lymphocytic Leukemia
DrugGNC-035
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
3
Tianjin
2023-08-16
Recruiting
Gene Therapy(FT-003) for Wet AMD
NCT06492863Neovascular Age-related Macular Degeneration
Frontera Therapeutics
Phase 1/2
78
Tianjin
2023-08-15
Rows per page Showing 601–700 of 940
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=7

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.